These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15696549)

  • 21. Medical therapy for rheumatoid arthritis--value for money?
    Lambert CM
    Rheumatology (Oxford); 2001 Sep; 40(9):961-4. PubMed ID: 11561105
    [No Abstract]   [Full Text] [Related]  

  • 22. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 23. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
    Boers M
    Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
    [No Abstract]   [Full Text] [Related]  

  • 25. A modest proposal.
    Lipsky PE
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):343. PubMed ID: 16932714
    [No Abstract]   [Full Text] [Related]  

  • 26. Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.
    van den Hout WB
    Nat Clin Pract Rheumatol; 2009 Feb; 5(2):78-9. PubMed ID: 19107111
    [No Abstract]   [Full Text] [Related]  

  • 27. Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab?
    Boumans MJ; Vos K; Gerlag DM; Tak PP
    Ann Rheum Dis; 2012 Mar; 71(3):472-3. PubMed ID: 21908451
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic consequences of established rheumatoid arthritis and its treatment.
    Kavanaugh A
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):929-42. PubMed ID: 17870036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid arthritis: the future is not yet now.
    Rubinow A
    Isr Med Assoc J; 2001 Sep; 3(9):669-71. PubMed ID: 11574984
    [No Abstract]   [Full Text] [Related]  

  • 30. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Solutions for off-label therapy].
    Schmidt WA
    Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
    Andrews G; Simonella L; Lapsley H; Sanderson K; March L
    J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient perspectives on cytokine medicines.
    Bosworth A
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):182-5. PubMed ID: 15588694
    [No Abstract]   [Full Text] [Related]  

  • 35. Back to the future: the managed care approach to rheumatoid arthritis.
    Sidorov J
    Manag Care Interface; 2007 Jul; 20(7):28-30. PubMed ID: 17849731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology.
    Gabriel S; Tugwell P; O'Brien B; Yelin E; Drummond M; Ruff B; Brooks P; Bombardier C; Boers M
    J Rheumatol; 1999 Jan; 26(1):203-6. PubMed ID: 9918264
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.
    Fries JF
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I86-9. PubMed ID: 10577980
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
    van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
    Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement at Any Cost? The Art and Science of Choosing Treatment Strategies for Rheumatoid Arthritis.
    Losina E; Katz JN
    Ann Intern Med; 2017 Jul; 167(1):55-56. PubMed ID: 28554193
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.